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Background:  Although the beneficial effect of ICD therapy has been well established as primary prevention in a selected population at high risk 
for sudden cardiac death, a substantial part does not benefit from ICD treatment.
Methods:  Since 1996, all ICD recipients in the Leiden University Medical Center have been clinically assessed at implantation. For the current 
study, patients with ischemic heart disease and a primary indication for implantation have been included. During follow-up, all-cause mortality 
and device therapy (ATP or shock) were noted. Non-benefit was defined as death, prior to first appropriate ICD therapy. Out of baseline variables, a 
baseline risk score was constructed to estimate risk for non-benefit.
Results:  Nine-hundred patients (87% men, mean age 64±10 years) were included in the analysis. During a median follow-up of 669 days 
(IQR, 363-1322 days), 150 patients (17%) died and 191 (21%) patients received appropriate device therapy. A total of 114 (13%) patients were 
considered the non-benefit group. Stratification for non-benefit resulted in risk categorization of patients as low, intermediate or high-risk. Age ≥ 
75 years was the strongest predictor of non-benefit. Five years cumulative incidence for non-benefit ranged from 12% (95%CI 5-18%) in low-risk 
patients to 49% (95%CI 38-60%) in high-risk patients (Figure).
Conclusion: The risk of non-benefit can be predicted in primary prevention ICD patients with ischemic heart disease by using patient-tailored risk 
estimation. 
